PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Delamanid→

Delamanid PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
681492-22-8
Molecular formula
C25H25F3N4O6
Molecular weight
534.5 g/mol
Drug class
Nitro-dihydro-imidazooxazole antimycobacterial agentmycolic-acid synthesis inhibitor
Mechanism of action
A prodrug activated by the mycobacterial F420-dependent nitroreductase pathway. Its active metabolites inhibit synthesis of methoxy- and keto-mycolic acids, disrupting the mycobacterial cell wall.
Indications / reported uses
  • Part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants weighing at least 10 kg when an effective regimen cannot otherwise be composed because of resistance or tolerability; follow current national TB guidance

Sources: EMA Deltyba EPAR · EMA product information · Government of India — Guidelines for use of delamanid in drug-resistant TB · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Delamanid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Delamanid Permitted Daily Exposure (PDE) report (the Delamanid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Delamanid Occupational Exposure Limit (OEL) report (the Delamanid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.